Earl Martin Douglas is General Counsel at BIOMIMETIC THERAPEUTICS, INC. (BMTI). They have made 9 open-market trades across 2 companies since 2008, most recently 2026-08-21.
CIK 0001362155
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $63K since 2008, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ALLO | 488,267 | $579K |
| BMTI | 53,517 | — |
| Total | $579K |
Shares reported on the most recent Form 4, priced at the 2026-08-25 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALLO | SELL | 2026-08-21 | 2026-08-25 | $2.12 | $63K | -9.0% | -23.3% | — |
| ALLO | SELL | 2026-02-02 | 2026-02-04 | $1.76 | $40K | +20.0% | +27.8% | +20.8% |
| ALLO | SELL | 2025-02-03 | 2025-02-05 | $1.71 | $11K | +72.1% | +32.1% | -22.4% |
| BMTI | SELL | 2012-03-26 | 2012-03-28 | $2.35 | $126K | N/A | N/A | N/A |
| BMTI | SELL · 10b5-1 | 2011-10-12 | 2011-10-14 | $3.01 | $27K | N/A | N/A | N/A |
| BMTI | SELL · 10b5-1 | 2011-10-06 | 2011-10-11 | $3.00 | $36K | N/A | N/A | N/A |
| BMTI | SELL · 10b5-1 | 2011-10-03 | 2011-10-05 | $2.92 | $26K | N/A | N/A | N/A |
| BMTI | SELL | 2010-03-17 | 2010-03-19 | $13.30 | $67K | N/A | N/A | N/A |
| BMTI | SELL | 2010-01-13 | 2010-01-14 | $12.10 | $155K | N/A | N/A | N/A |
| BMTI | SELL | 2009-03-17 | 2009-03-18 | $8.45 | $10K | N/A | N/A | N/A |
| BMTI | BUY | 2008-03-28 | 2008-04-01 | $9.05 | $9K | N/A | N/A | N/A |
| BMTI | BUY | 2008-01-23 | 2008-01-24 | $15.28 | $53K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.